Subscribe to RSS
DOI: 10.4103/ijmpo.ijmpo_101_20
Immunotherapy in Nonsmall Cell Lung Cancer (Basket of Choices)
Financial support and sponsorship Nil.
Abstract
The advent of immunotherapy has changed the landscape of lung cancer management over the past few years. Once a uniformly fatal disease with limited therapeutic options, the physicians now have a myriad of options to choose from while offering therapy to a patient of metastatic nonsmall cell lung cancer.
Keywords
Atezolizumab - checkpoint inhibitors - chemotherapy - nonsmall cell lung cancer - PDL1 testing - pembrolizumabPublication History
Received: 19 March 2020
Accepted: 11 August 2020
Article published online:
17 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-50
- 2 Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP. et al Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28
- 3 Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33
- 4 Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37: 537
- 5 Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92
- 6 Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M. et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2020; 38: 1505-17
- 7 Zhou Y, Lin Z, Zhang X, Chen C, Zhao H, Hong S. et al. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: Pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer 2019; 7: 120
- 8 West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924-37
- 9 Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-301
- 10 Reck M, Mok TS, Nishio M, Jotte RM, Cappuzzo F, Orlandi F. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019; 7: 387-401
- 11 Papadimitrakopoulou VA, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G. et al. Impower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. 2018 World Conference on Lung Cancer. Abstract OA05.07. Presented September 24, 2018.